Brief Report: Long-Term (96-Week) Efficacy and Safety after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

Journal of Acquired Immune Deficiency Syndromes

Volumn 75, Issue 2, 2017, Pages 226-231

  Raffi, François ^a   Orkin, Chloe ^b   Clarke, Amanda ^c   Slama, Laurence ^d   Gallant, Joel ^e   Daar, Eric ^f   Henry, Keith ^g   Santana Bagur, Jorge ^h   Stein, David K ⁱ   Bellos, Nicholaos ^j   Scarsella, Anthony ^k   Yan, Mingjin ^l   Abram, Michael E ^l   Cheng, Andrew ^l   Rhee, Martin S ^l  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UK   (United Kingdom)

^d HÔTEL DIEU   (France)

^e Southwest CARE Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HENNEPIN COUNTY MEDICAL CENTER   (United States)

^h UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

ⁱ JACOBI MEDICAL CENTER   (United States)

^j Southwest Infectious Disease Associates   (United States)

^k Pacific Oaks Medical Group   (United States)

^l GILEAD SCIENCES   (United States)

more..

Author keywords

HIV; osteopenia; proteinuria; tenofovir alafenamide

Indexed keywords

CREATININE; EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GS-7340; TENOFOVIR;

ALBUMINURIA; ANTIRETROVIRAL THERAPY; ATRIAL FIBRILLATION; BONE DENSITY; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; KIDNEY TUBULE FUNCTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MOOD DISORDER; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TENESMUS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; VIROLOGY; VIRUS LOAD;

ADENINE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85014657477     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001344     Document Type: Conference Paper

References (20)

1. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-780.
2. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008; 22:99-103.
3. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
4. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-972.
5. Schafer JJ, Manlangit K, Squires KE. Bone health and human immunodeficiency virus infection. Pharmacotherapy. 2013;33:665-682.
6. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-1801.
7. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-2615.
8. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304.
9. Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19:687-692.
10. U. S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. Guidance for Industry. Latest revision November 2015. Available at https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf. Accessed September 1, 2016.
11. Gänthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and Prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016; 316:191-210.
12. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3: e158-e165.
13. Smith F, Hammerstorm T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011; 45:291-300.
14. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. DRAFT GUIDANCE. 2013;1-43. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM355128. pdf. Accessed September 1, 2016.
15. European AIDS Clinical Society. European Guidelines for Treatment of HIV-infected Adults in Europe 8.0. 2015. Available at: http://www. eacsociety.org/fi les/2015-eacsguidelines-8.0-english-rev-20151221. pdf. Accessed September 6, 2016.
16. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58-64.
17. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781-1784.
18. Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebocontrolled trial. Clin Infect Dis. 2015;61:403-408.
19. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/ emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17: 1011-1020.
20. Mulligan K, Glidden DV, Anderson PL, et al. Decreases in cholesterol in HIV-seronegative men using emtricitabine/tenofovir pre-exposure prophylaxis: lipid results of iPrEx. 15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; October 15-17, 2013; Brussels, Belgium. Available at: http://www.intmedpress.com/serveFile.cfm?sUID=bc75b62c-c206-437a-b725-a75baa67f5b2. Accessed January 4, 2017.